Humoral response after BNT162b2 vaccine in Japanese of hemodialysis patients

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients - Effectiveness of BNT162b2 vaccine in Japanese hemodialysis patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046999

Enrollment

185

Registered

2022-12-01

Start date

2021-05-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing hemodialysis at our hospital

Exclusion criteria

Exclusion criteria: Patients with no history of COVID-19

Design outcomes

Primary

Measure	Time frame
Acquisition rate of SARS-CoV-2 IgG antibody after BNT162b2 vaccination	—

Secondary

Measure	Time frame
Adverse events of BNT162b2 vaccine	—

Countries

Japan

Contacts

Public ContactRYOICHI MIYAZAKI

Fujita Memorial Hospital Internal Medicine

ryoichi@mitene.or.jp0776-21-1277

Outcome results